1OH JM, KYUN J, CHO SW. Long-term lamivudine therapy for chronic hepatitis B in patients with and without cirrhosis [J]. Pharmacotherapy,2002,22(10) : 1226-1234.
2NEVENS F, MAIN J, HOONKOOP P, et al. Lamivudine therapy for chronic hepatitis B: A six-month randomized close-ranging study[ J ]. Gastroenterology, 1997,113(4) : 1258-1263.
3Lai C L，Hepatology，1997年，25卷，241页
4中华内科杂志，1995年，34卷，788页
5王泰龄，中华肝脏病杂志，1998年，6卷，195页
6Polhemus ME, Aronson NE. Persistent nephrolithiasis after discontinuation of indinavir therapy. Clinical Infectious Diseases, 1998, 27: 1536.
7Lerner LB, Cendron M, Rous SN. Nephrolithiasis from indinavir, a new human immunodeficiency virus drug. Journal of Urology, 1998, 159: 2074.
8Grunke M, Valerius T, Manger B, et al. Renal dysfunction in a human immunodeficiency virus- infected patient who was treated with indinavir. Clinical Infectious Diseases, 1997, 25:1270.
9Witte M, Tobon A, Gruenenfelder J, et al. Anuria and acute renal failure resulting from indinavir sulfate induced nephrolithiasis. Journal of Urology, 1998,159: 498.
10Bruce RG, Munch LC, Hoven AD, J, et al.Urolithiasis associated with the protease inhibitor indinavir. Urology, 1997, 50: 513.
